Literature DB >> 33229708

Management of infectious keratitis following uneventful small-incision lenticule extraction using a multimodal approach - A case report.

Sri Ganesh1, Sheetal Brar1, B N Nagesh1.   

Abstract

A 42-year-old female presented with pain, photophobia, and superficial corneal infiltrates in mid-periphery in the left eye, after 2 days of uneventful bilateral SMILE procedure. Inspite of the medical treatment with fortified antibiotics, the infection spread to the interface, close to visual axis reducing UDVA from 20/16 to 20/80. Immediate surgical intervention in the form of scraping of interface lesions with 26G needle, interface wash with antibiotics and photoactivated chromophore for keratitis (PACK-CXL) was performed. After 24 h of bacterial culture Staphylococcus aureus was yielded. Interface wash and PACK-CXL was repeated after 48 h by which infiltrates reduced and early scarring was observed by 10th post-op day. Subsequent topical steroids helped in limiting scar formation and UDVA improved to 20/30 at the final visit. Combined approach of interface wash with antibiotics and PACK-CXL may be a safe and effective modality in treating early onset infectious keratitis following SMILE surgery.

Entities:  

Keywords:  Infectious keratitis; PACK-CXL; SMILE; interface wash

Mesh:

Substances:

Year:  2020        PMID: 33229708      PMCID: PMC7856942          DOI: 10.4103/ijo.IJO_2418_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


Infectious keratitis after laser vision correction (LVC)[123] warrants aggressive treatment to preserve useful vision. In context of infection after small incision lenticule extraction (SMILE) procedure, the management involves either interface wash[4] or PACK-CXL,[5] but not a combination of the two due to fear of spread of infection. We report aunique case of early onset infectious keratitis after an uneventful SMILE procedure, which was aggressively managed using a multimodal approach, resulting in favorable clinical outcomes.

Case Report

A 42 year old, systemically healthy female underwent uneventful SMILE for simple myopia of -4.00 D in both eyes, following which she achieved 20/16 UDVA in each eye on first post-op day. However, she returned after 24 h with complains of pain, redness, and lid swelling in the left eye, following a foreign body going into the eye. On examination, UDVA in the left eye was 20/16, and ocular evaluation did not reveal foreign body. However, mild lid oedema, circum-corneal congestion, a small superficial infiltrate measuring 0.5 × 0.5 mm in the temporal mid-peripheral cornea at the edge of the side cut of the lasered area and 2+ reaction in the anterior chamber was observed [Fig. 1]. Corneal scrapings were sent for Gram staining and culture in blood agar only, as the sample was not sufficient for KOH preparation and fungal culture. Gram staining revealed Gram positive cocci, based on which a combination therapy of fortified cefotaxime: 50mg/mL and vancomycin: 50mg/mL topical drops (Q 1 hourly alternately) was started along with topical homatropine (2%) for cycloplegia. Topical steroids, which were prescribed postoperatively were stopped.
Figure 1

Small infiltrate in mid peripheral cornea (arrow) on 2nd post-operative day in the left eye following uneventful bilateral SMILE procedure

Small infiltrate in mid peripheral cornea (arrow) on 2nd post-operative day in the left eye following uneventful bilateral SMILE procedure On the next day, the left eye developed 4 new and distinct, white, circular infiltrates of variable sizes (0.5–2mm), and involving the interface, as demonstrated by the AS-OCT [Fig. 2a and b]. UDVA had dropped to 20/80. After 24 h, culture did not reveal any growth.
Figure 2

(a) Appearance of four new lesions (arrows) on 3rd post-operative day (b) Corresponding AS-OCT showing infiltrates in interface and stromal bed with largely undisturbed cap

(a) Appearance of four new lesions (arrows) on 3rd post-operative day (b) Corresponding AS-OCT showing infiltrates in interface and stromal bed with largely undisturbed cap In view of the progression and failure of medical therapy, surgical intervention was contemplated. Interface was carefully opened with blunt dissection followed by which, a 26G needle was used to scrape the lesions from the undersurface of the cap. Samples were obtained for both bacterial and fungal culture in blood agar and Sabouraud's dextrose agar respectively. The interface was then washed using vancomycin (1 mg in 0.1 ml solution) and moxifloxacin (0.05 ml of Vigamox 0.5%, Alcon, Fort Worth, Texas, USA). Subsequently, photoactivated chromophore for keratitis or PACK-CXL[4] was performed by using 2.5% riboflavin reconstituted in normal saline, applied in the interface for 1 min, followed by UV-A exposure at a fluence of 30 mW for 3 min, delivering a total energy of 5.4 J/cm2 (Avedro KXL system, Waltham). Topical therapy with fortified antibiotics was continued. On postoperative day 1 following intervention, the cornea was hazy and edematous, however, the infiltrates had reduced, and no fresh lesions were noticed [Fig. 3]. After 24 h, bacterial culture showed the growth of Staphylococcus aureus, sensitive to vancomycin, cefotaxime, and moxifloxacin. Fungal culture did not reveal any growth. Interface wash with the same antibiotics was repeated after 48 h in order to consolidate the results, and as it was a case of infection post a refractive surgery, we were being extra cautious.
Figure 3

Post-operative day 1 clinical picture following PACK-CXL and interface irrigation showing reduction of infiltrates and mild stromal edema

Post-operative day 1 clinical picture following PACK-CXL and interface irrigation showing reduction of infiltrates and mild stromal edema By 10th post-op day, when infiltrates had reduced, and early scarring was seen, topical steroid (fluoromethalone 0.1%) was started and tapered over 3 weeks. At 3 months, scars had reduced in size, corneal oedema had resolved [Fig. 4a], and the patient recovered a UDVA of 20/30 in the affected eye, which improved to 20/20 with spectacle correction of 0.75D cyl at 140°. Fig. 4b shows the AS-OCT of the left eye at 3-months, showing hyper-reflective areas in the interface, suggestive of post CXL haze and healed keratitis scars.
Figure 4

Three month post clinical picture showing (a) Complete resolution of infection with minimal scar and (b) PACK-CXL associated mild anterior stromal haze

Three month post clinical picture showing (a) Complete resolution of infection with minimal scar and (b) PACK-CXL associated mild anterior stromal haze

Discussion

Infectious keratitis post SMILE may be more challenging to manage, as the infection may spread rapidly within the closed interface, which is relatively difficult to access, compared with flap in LASIK. In these cases, one should not hesitate to open the interface for corneal scrapings, which help in targeted treatment against infectious agent. While obtaining scrapings, however, care must be taken while using sharp needle in the interface, as perforation of cap may lead to scarring and decrease in visual acuity. This case reiterates that early onset keratitis after refractive surgery is predominantly caused by Gram positive bacteria,[1] and when nature of organism and its antibiotic sensitivity is not available, vancomycin and moxifloxacin appear to be good choice for interface irrigation as recommended by Soloman, et al. to cover Methicillin resistant S. aureus.[4] There are very few reported cases of culture proven infectious keratitis after SMILE surgery.[45678] These were treated either with antibiotics interface wash[4] or PACK-CXL,[5] but not with the combination of the two. Chan, et al. reported the successful use of PACK-CXL in treatment of Staphylococcal keratitis after SMILE.[6] However, they did not perform interface irrigation fearing an iatrogenic spread of infection. We performed both interface irrigation with antibiotics and PACK-CXL in the same sitting, as the former would reduce the infective load and enhance the bactericidal effect of PACK-CXL. Interface irrigation was repeated after 48 hs for continued response. As, the role of steroids is controversial and they did not make a difference in scar size and final visual outcome,[9] we were cautious in starting steroids early and used milder steroids, only when early scarring was noted.

Conclusion

To the best of our knowledge, we described the first case of bacterial keratitis after SMILE, which was treated successfully with corneal scraping, interface wash and PACK-CXL, without additional complications. However, further data are required to establish this, and early recognition and treatment, along with close follow-up, remains the key to successful management in these challenging cases.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

Review 1.  Collagen Cross-linking With Photoactivated Riboflavin (PACK-CXL) for Bacterial Keratitis After Small Incision Lenticule Extraction (SMILE).

Authors:  Tommy C Y Chan; Vanissa W S Chow; Vishal Jhanji
Journal:  J Refract Surg       Date:  2017-04-01       Impact factor: 3.573

Review 2.  Bilateral Non-tuberculous Mycobacterial Keratitis After Small Incision Lenticule Extraction.

Authors:  Hsin-Yu Liu; Hsiao-Sang Chu; Wei-Li Chen; Fung-Rong Hu; I-Jong Wang
Journal:  J Refract Surg       Date:  2018-09-01       Impact factor: 3.573

3.  Microbial keratitis trends following refractive surgery: results of the ASCRS infectious keratitis survey and comparisons with prior ASCRS surveys of infectious keratitis following keratorefractive procedures.

Authors:  Renée Solomon; Eric D Donnenfeld; Edward J Holland; Sonia H Yoo; Sheraz Daya; José L Güell; Francis S Mah; Stephen V Scoper; Terry Kim
Journal:  J Cataract Refract Surg       Date:  2011-07       Impact factor: 3.351

4.  Infectious keratitis in 18,651 laser surface ablation procedures.

Authors:  Victoria de Rojas; Fernando Llovet; Mercedes Martínez; Rosario Cobo-Soriano; Julio Ortega-Usobiaga; Jaime Beltrán; Julio Baviera
Journal:  J Cataract Refract Surg       Date:  2011-08-23       Impact factor: 3.351

5.  The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; Kieran S O'Brien; David V Glidden; Kathryn J Ray; Catherine E Oldenburg; Michael E Zegans; John P Whitcher; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2013-10-01       Impact factor: 5.258

6.  Infectious keratitis in 204 586 LASIK procedures.

Authors:  Fernando Llovet; Victoria de Rojas; Emanuela Interlandi; Clara Martín; Rosario Cobo-Soriano; Julio Ortega-Usobiaga; Julio Baviera
Journal:  Ophthalmology       Date:  2009-12-14       Impact factor: 12.079

7.  Safety and complications of more than 1500 small-incision lenticule extraction procedures.

Authors:  Anders Ivarsen; Sven Asp; Jesper Hjortdal
Journal:  Ophthalmology       Date:  2013-12-21       Impact factor: 12.079

8.  Bilateral infectious keratitis after small-incision lenticule extraction.

Authors:  Ismaël Chehaibou; Otman Sandali; Barbara Ameline; Nacim Bouheraoua; Vincent Borderie; Laurent Laroche
Journal:  J Cataract Refract Surg       Date:  2016-04       Impact factor: 3.351

  8 in total
  1 in total

Review 1.  Update on diagnosis and management of refractory corneal infections.

Authors:  Shweta Agarwal; Tanveer A Khan; Murugesan Vanathi; Bhaskar Srinivasan; Geetha Iyer; Radhika Tandon
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.